Basel, April 30, 2018 – Novartis announced new positive brolucizumab (RTH258) data in neovascular age-related macular degeneration (nAMD) from a pre-specified secondary analysis of the Phase III HAWK and HARRIER trials. The findings showed that patients assessed as appropriate for a 12-week treatment frequency during the first 12-week cycle after loading could reliably stay on […]
The post New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval appeared first on PharmaVOICE.
